Table 5 Factors affecting OS by Cox’s regression analysis.

From: Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients

Items

Cox’s regression model

P value

HR

95% CI

Lower

Higher

Univariate Cox’s regression

Age (≥18 vs. <18 years)

1.000

1.000

0.374

2.673

Gender (male vs. female)

0.850

0.914

0.359

2.324

Number of previous chemotherapies (≥4 vs. <4)

0.996

0.997

0.393

2.531

Refractory disease (yes vs. no)

0.028

2.914

1.122

7.571

Relapsed disease (yes vs. no)

0.199

0.365

0.079

1.697

Bone marrow blasts (≥5% vs. <5%)

0.065

2.557

0.945

6.921

Extramedullary disease (yes vs. no)

0.529

0.743

0.295

1.874

CNSL (yes vs. no)

0.084

0.333

0.096

1.158

BCR/ABL1 (positive vs. negative)

0.249

0.539

0.188

1.541

SH2B3 mutation (positive vs. negative)

0.198

0.480

0.157

1.468

PAX5 mutation (positive vs. negative)

0.167

0.417

0.120

1.444

WBC (≥30 × 109/L vs. <30 × 109/L)

0.695

1.205

0.474

3.066

Lymphodepletion regimens (Flu + Cy vs. non-Flu + Cy)

0.049

2.574

1.005

6.598

CAR-T cells (anti-CD19 + CD22 vs. anti-CD19)

0.263

1.925

0.611

6.059

CR with MRD negative (yes vs. no)

0.080

0.411

0.152

1.111

Bridging to HSCT (yes vs. no)

0.014

0.279

0.101

0.769

Multivariate Cox’s regression

Bridging to HSCT (yes vs. no)

0.014

0.279

0.101

0.769

  1. Factors affecting OS were determined by univariate and multivariate Cox’s proportional hazards regression model with Forward Stepwise (Conditional) method. P value <0.05 was considered significant.
  2. OS overall survival, CR complete remission, MRD minimal residual disease, CNSL central nervous system leukemia, WBC white blood cell, Flu fludarabine, Cy cyclophosphamide, CAR-T chimeric antigen receptor T cells, HSCT hematopoietic stem-cell transplantation, HR hazard ratio, CI confidence interval.
Back to article page